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Abstract
Background: Persistent fatigue is recognised as one of the most common, ongoing symptoms reported
by patients following cancer treatment and may have profound effects on the quality of life. However,
recent cross-sectional studies also highlight the close relationship between cancer related fatigue (CRF)
and diagnoses of depression or anxiety disorder. There is currently limited information about the
relationships between these conditions over time. We sought to examine the longitudinal relationships
between fatigue and mood disorder in women treated with adjuvant therapy for early stage breast cancer.
Methods: Women who had recently completed adjuvant therapy for Stage I or II breast cancer (n = 212)
were sent a questionnaire with established case thresholds for clinically-significant fatigue and
psychological disorder, as well as a questionnaire assessing disability. Potentially relevant variables linked
to fatigue states, including age, treatment modality, menopausal status, and hematological indices were
recorded. The illness outcomes were assessed over 48 months of follow-up.
Results: The 176 women who responded to the questionnaire (84%) had a mean age of 55 (range 24–83)
years and had completed adjuvant treatment on average 10 (range 4.7 – 16.3) months previously.
Radiotherapy had been administered, either alone (50% of women) or in combination with chemotherapy
(36%). Responses from 87 women (48%) indicated a significant fatigue state (termed here post-cancer
fatigue; PCF), and from 59 women (33%) responses indicated significant psychological distress. Thirty-four
women (19%) were cases of fatigue alone (i.e. unaccompanied by psychological disorder), whereas 52
(30%) were cases of both disorders. Multivariate analysis did not reveal any association between
demographic, clinical or laboratory variables, and caseness for PCF. Self-reported functional disability was
significantly associated with fatigue. Follow-up at 24, 36 and 48 months revealed high rates of ongoing PCF
in conjunction with psychological distress, despite falling rates of psychological distress alone and fatigue
alone.
Conclusion: Post-cancer fatigue was prevalent and sustained on follow-up. Concurrent psychological
disorder was evident in the majority, but not all, cases of PCF and tended to be sustained over time.
Further prospective cohort studies to define the longitudinal co-morbid relationships between fatigue,
mood disorder, and ongoing disability after cancer treatment are indicated.
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Background
Persistent fatigue is recognised as one of the most com-
mon, ongoing symptoms reported by patients following
cancer treatment [1,2]. In those who have been otherwise
successfully treated for malignant disorders, this problem
may have profound effects on the quality of life [1].
Fatigue is a complex phenomenon, with physiological,
psychological and behavioural dimensions [3]. When
severe and persistent, fatigue states result in marked
social, emotional and physical disability [4]. Fatigue is
reported frequently in association with a broad range of
medical conditions [5] and with a range of psychological
disorders, notably major depression [6]. Previous research
in primary care has indicated that prolonged fatigue states
lasting one month or more occur in 25% of patients
attending general practice, and that a third of these cases
are not explained by other medical or psychological disor-
ders [7].
In clinical oncology, fatigue is one of the most common
unrelieved symptoms of cancer [8]. Such fatigue is an
almost universal side effect experienced by patients during
both radiotherapy [9-13] and chemotherapy [14-18],
where the reported prevalence ranges between 70 and
100% [3,8,18]. Following completion of therapy, cross-
sectional studies involving cancer patients with differing
stages of disease, indicate that over 75% report fatigue as
a significant ongoing symptom [19-21]. Application of
the diagnostic criteria for cancer-related fatigue (CRF)
indicates that between 14 and 30% of patients have ongo-
ing CRF with associated disability when surveyed 1–5
years after completion of treatment, [21,22] well in excess
of the rates in the general population [22]. Similarly, high
prevalence rates of CRF have been reported in women
receiving adjuvant therapy for breast cancer [13-18,23-
32]. Recent prospective studies in both breast cancer and
Hodgkin's disease survivors also consistently identified
high rates of fatigue lasting months to years after treat-
ment [33-36]. When the CRF persists well beyond the end
of treatment (termed here post-cancer fatigue {PCF), it
appears unlikely that the fatigue state can be simply
accounted for by sustained consequences of the more
obvious toxicities of adjuvant therapy such as anemia or
menopause [27,35,37]. However, recent studies also high-
light the close relationship between PCF and diagnoses of
depression or anxiety disorder [24-26,38]. Accordingly, a
cross-sectional cohort of women who had received adju-
vant chemotherapy and/or radiotherapy for early stage
breast cancer was recruited and then followed prospec-
tively to determine the longitudinal relationships
between these conditions. We hypothesized that the nat-
ural history of fatigue would vary according to the pres-
ence of other coexisting variables such as psychological
symptoms and that the majority of cases would improve
over time.
Methods
Women (n = 212) who had attended the Medical Oncol-
ogy Department at the Prince of Wales Hospital or the
Cancer Care Center of St George Hospital, Sydney, Aus-
tralia, for adjuvant treatment of surgically-resected stage I
or stage II breast cancer were invited to complete a mail-
out questionnaire, provided that they had completed
adjuvant therapy in the preceding 12 months. The rele-
vant institutional review boards approved the study and
consent form which all patients signed.
Screening questionnaires
The Somatic and Psychological Health Report (SPHERE)
questionnaire was used to screen for clinically-significant
fatigue states and mood disorders (see Additional file 1).
This instrument was developed specifically to assess a
wide range of somatic and psychological symptoms in
medical and psychiatric settings [39] and has recently
been used in assessing fatigue states in protracted fatigue
following infectious illness [40] and in patients following
adjuvant treatment for cancer [24]. The reliability and
construct validity of the instrument in the identification
of prolonged fatigue states have been demonstrated [41].
The Brief Disability Questionnaire (BDQ) [42] was used
to assess social and occupational role impairment based
on an 11-item self-rated tool. The scores on the BDQ have
a possible range of 0–22 with each of 11 items scored
0,1,2 for the descriptors 'No, not at all', 'Yes, sometimes or
a little', 'Yes, moderately or definitely'. The 11 items
describe the capacity to participate in items ranging from
"vigorous activity" to "eating, dressing, bathing". Self-
reported disability on the BDQ has been demonstrated to
consistently correlate with functional disability in the
work role (including housework) [42].
Clinical details
The treating oncologist provided clinical information,
including details of the: surgical resection; tumor stage
and nodal status; menopausal status prior to, and follow-
ing, treatment; radiotherapy details (fields, dose, fractions
and irradiated volume); and the chemotherapy details
(drugs, doses, frequency, duration and on-treatment tox-
icity).
Statistical analysis
Caseness for a clinically-significant fatigue state (i.e. PCF)
was defined according to the previously validated cut-off
scores on the SOMA subscale of the SPHERE [7,39]. Case-
ness for psychological disorder was similarly designated
using the PSYCH subscale of the SPHERE [7,39]. Correla-
tions between PCF, psychological and hematological var-
iables were examined using multivariate modeling
techniques. Logistic regression was used to seek predictive
variables (and their associated relative risk) for PCF. AllBMC Cancer 2006, 6:240 http://www.biomedcentral.com/1471-2407/6/240
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analyses were conducted using the SPSS for Windows ver-
sion 10.0 [43].
Results
Demographics and baseline characteristics
One hundred and seventy six women (80% of the 212 sur-
veyed) responded to the initial questionnaire. These
women did not differ from those who did not respond in
terms of age or treatment characteristics (data not shown).
The respondents ranged in age from 26 to 85 years (mean
55 years). None of the women had disease progression
evident at the time of the initial survey. Of the sample,
35% (n = 61) women were pre-menopausal, 12% (n = 21)
peri-menopausal, and 52 % (n = 91) were post-menopau-
sal prior to treatment. Of the former groups 51% (n = 42)
had menopause induced by the adjuvant treatment. Fifty
percent of the 176 women (n = 88) had received radiation
therapy with or without subsequent tamoxifen; 36% (n =
63) had combined radiation and chemotherapy; and 13%
(n = 23) had received chemotherapy with or without sub-
sequent tamoxifen (Table 1).
Of the 176 respondents to the initial survey, 49% (n = 86)
reported symptoms indicative of clinically-significant
fatigue. Sixty-three women (36%) reported significant lev-
els of anxiety or depression (see Figure 1) – of whom the
majority (n = 53; 81%) were also cases of fatigue. Analysis
of the responses given by 34 women (19%) indicated that
they had prolonged fatigue as an isolated phenomenon
(i.e. unaccompanied by psychological distress).
The mean disability score on the BDQ was significantly
higher in the fatigue cases 9.2 (±5.7), than in the unaf-
fected group (4.7 ± 4.7) (p < 0.0001), consistent with pre-
vious data indicating that the threshold for fatigue
caseness on the SPHERE is associated with both patient
and physician-rated functional impairment [39]. The
women with fatigue with or without accompanying mood
disorder reported significantly different patterns of func-
tional status on individual items of the questionnaire. In
particular, 32 of 80 women (40%) who were fatigue cases
at enrolment reported 'moderate or definite' difficulty
with walking up stairs compared with only 9 of 87 (10%)
of those who were not fatigued (Chi-square 19.79 p <
0.001).
There was also no correlation with menopausal status pre-
therapy, or with the advent of menopausal symptoms
assessed at the time of the screening questionnaire. No
relationship to treatment type, nodal status or tumor size
was detected.
Logistic regression analysis (Table 2) incorporating the
baseline clinical variables of treatment type, and meno-
pausal status, as well as psychological symptom score at
screening, identified psychological distress as the only sig-
nificant risk factor for PCF (p < 0.0001).
Longitudinal course
The 176 initial respondents were re-screened using the
same instruments at 24 months post-treatment, when 137
(78%) of the original respondents returned completed
questionnaires, at 36 months when 118 responded
(67%), and finally at 48 months when 116 responded
(66%). By the time of the 48-month post-treatment fol-
low-up, 15 women of the original 176 who had
responded (9%) were known to have relapsed or died
from cancer recurrence and related complications.
Although the falling rates of response make these data
prone to selection bias at this late follow-up timepoint, of
the respondents (41%) reported ongoing fatigue (vs. 49%
at 10 months post treatment) with the proportion of
women free of concurrent psychological distress remain-
ing essentially unchanged at approximately 18% of the
group as a whole. When these data were analysed more
conservatively (by maintaining the denominator for the
Table 1: Demographic and clinical characteristics of women with and without post-cancer fatigue (PCF) after adjuvant treatment for 
breast cancer
Patient groups; mean (SD) or percentage
PCF (n = 98) Non-fatigued (n = 77) P
Age (years) 56 (11.5) 55 (11.5) ns
Months since treatment completion 10 7 (6.1) 10.5 (5.6) ns
Surgical treatment (% of group)
Mastectomy 45.5 41.5 ns
Lumpectomy 54.5 58.5 ns
Adjuvant treatment (% of group)
Chemotherapy 14.3 12.6 ns
Radiotherapy 45.5 53.7 ns
Combined chemotherapy and radiotherapy 40.3 33.7 ns
Menopausal status at follow-up (% of group)
Pre-/peri-menopausal 34 39 ns
Postmenopausal 66 61 nsBMC Cancer 2006, 6:240 http://www.biomedcentral.com/1471-2407/6/240
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case rates at 176, that is, assuming non-respondents are
asymptomatic) then 17% of the women were designated
as having ongoing PCF, including 4% who had no associ-
ated psychological distress. There were 37 of 116 women
at 48 months whose responses indicated significant levels
of psychological disorder (32%) (vs. 36% at 10 months)
and 27 (23%) with combined caseness (vs. 30% at 10
months). Again, conservative re-analyses of these data
Longitudinal prevalence of fatigue and mood disorder in women followed after adjuvant treatment for early stage breast cancer  (n = 176) Figure 1
Longitudinal prevalence of fatigue and mood disorder in women followed after adjuvant treatment for early stage breast cancer 
(n = 176). Although the number of respondents decreased at 24, 36, and 48 months, the denominator was kept constant for 
these estimates.
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Table 2: Logistic regression model – predicting post cancer fatigue at 10 months post treatment.
Beta co-efficient Standard error p value O.R.(95% C.I.)
Variables
Mood disorder* 0.507 0.113 <0.0001 1.67 (1.33, 2.07)
Surgery type** 0.025 0.443 0.955 1.03 (0.43, 2.45)
Tumor size 0.305 0.546 0.577 1.37 (0.47, 3.95)
Menopause stage 0.037 0.240 0.877 1.04 (0.65, 1.66)
Chemotherapy (Y/N) -0.063 0.595 0.915 0.94 (0.29, 3.01)
Radiotherapy (Y/N) -0.559 0.692 0.419 0.57 (0.15, 2.22)
Tamoxifen (Y/N) -0.006 0.470 0.990 0.99 (0.40, 2.50)
Constant -0.723 1.151 0.530 0.49
C.I confidence interval; O.R. Odds ratio.
* Identified by SPHERE.
**Lumpectomy vs. mastectomy.BMC Cancer 2006, 6:240 http://www.biomedcentral.com/1471-2407/6/240
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suggests that these figures would be 18% and 13% respec-
tively (see Figure 1).
We also analysed the temporal fluctuations in each case-
ness category over the follow-up period between 10 and
36 months post treatment. Data for this period was avail-
able for 116 women, of whom 102 responded for all three
timepoints and 14 did not respond at 24 months but did
so at 36 months (Table 3). Of the 24 women in this group
who reported fatigue initially, 13/24 (54%) reported res-
olution by 36 months post treatment, 6/24 (25%) had
persistent caseness for fatigue, 1/24 (4%) had developed
affective symptoms without fatigue, and 4/24 (16.7%)
had developed mood disorder in combination with sus-
tained fatigue.
Only 7/116 were identified with affective symptoms alone
at the 10-month timepoint. Of this group, 3/7 (43%) had
persistent mood disorder throughout follow-up, symp-
toms had resolved in 3/7 (43%), and 1/7 (14%) had
newly acquired fatigue at the 36-month time point.
Both fatigue and affective symptoms were reported by 34/
116 women at the 10-month timepoint. Of these women,
20/34 (59%) had persistent caseness for both compo-
nents of the illness complex over the next two years, 10/
34 (29%) subsequently reported fatigue only, and in 4/34
(12%) all symptoms resolved. No women from this group
remained with affective symptoms only.
When first screened 51/116 women had no significant
symptoms. Subsequently, 42/51 (82%) remained symp-
tom free, 4/51 (8%) developed fatigue, 3/51 (6%) devel-
oped both fatigue and mood disorder and 2/51 (4%)
developed affective symptoms alone.
Overall 15/116 (12.9%) women developed newly
acquired fatigue symptoms alone after the first time point,
7/116 (6%) acquired symptoms of both fatigue and
mood disorder, and only 3/116 (2.6%) acquired affective
symptoms alone.
Discussion
Consequent on the improvements in early identification
[44] and intervention strategies for breast cancer there has
been a marked increase in the number of women who
undergo adjuvant therapy. The data reported here indicate
that more than one third of these women experience pro-
longed morbidity characterized by fatigue after successful
surgical and adjuvant treatments – termed here PCF. Pre-
vious studies have also highlighted the prevalence of PCF
in women treated for breast cancer. For instance, Bower et
al [36] in a study of 763 women who had completed treat-
ment five to ten years previously, found that 34% of
women reported fatigue up to 10 years post treatment.
Andrykowski et al [45] used a case definition approach in
a prospective study of 288 women who had received adju-
vant treatment for breast cancer and identified a preva-
lence of fatigue of 26% at the completion of treatment. A
prospective study [35] found that of 430 patients with a 3-
year follow-up, 20% reported fatigue. There was no rela-
tionship with either chemotherapy regimen (high versus
low dose) or mean hemoglobin level. Poor mental health
(identified from Short-Form 36 – SF-36) was the best pre-
dictor of fatigue.
Table 3: Comparing changes in co-morbidity of fatigue and mood disorder over time in those who provided information at all three 
time points
Complete data available for 
three time points
10 months post-treatment 
(n = 116)
24 months post-treatment 
(n = 102)
36 months post treatment 
(n = 116)
Fatigue only n = 24 Unchanged 24/24 3/21 6/24
Fatigue and mood disorder N/A 2/21 4/24
Mood disorder only N/A 0/21 1/24
Resolved N/A 16/21 13/24
Mood disorder only n = 7 Unchanged 7/7 2/6 3/7
Fatigue only N/A 0/64 0/7
Fatigue and mood disorder N/A 1/6 1/7
Resolved N/A 2/6 3/7
Both fatigue and mood 
disorder n = 34
Unchanged 34/34 13/30 20/34
Fatigue only N/A 9/30 10/34
Mood disorder only N/A 3/30 0/34
Resolved N/A 5/30 4/34
Neither n = 51 Unchanged 51/51 30/45 38/49
Fatigue only N/A 10/45 4/51
Fatigue and mood disorder N/A 2/45 3/51
Mood disorder only N/A 3/45 2/51BMC Cancer 2006, 6:240 http://www.biomedcentral.com/1471-2407/6/240
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Fatigue is a common symptom accompanying both
depressive and anxiety disorders [46]. In our data set the
only significant predictor of fatigue was mood disorder
(Table 2). However, studies in primary care as well as in
oncology [8] and have identified prolonged fatigue states
unaccompanied by psychiatric disorder [7,47]. A review
of several studies of depression following adjuvant treat-
ment in patients with breast cancer reported an overall
prevalence of 26% [48]. The International Classification
of Diseases (ICD-10) criteria for Cancer-related Fatigue
specifically designates exclusion of patients with depres-
sion, as this disorder may provide an alternative explana-
tion for the symptom set [49,50]. If applied to the
questionnaire-based dataset reported here, 18% of
women experienced PCF in the absence of psychological
distress at 10 months post-completion of adjuvant treat-
ment.
This is one of very few studies to examine the longitudinal
evolution of PCF. This analysis indicated that the fatigue
state was largely stable – that is the initial designation of
fatigue was not likely to evolve into overt mood disorder
on follow-up. This finding argues that PCF has independ-
ent determinants from mood disorder, and is consistent
with similar findings in relation to CFS [47]. A similar pat-
tern of gradual resolution over time was evident for both
the fatigue and mood disturbance illness dimensions.
However, the kinetics of resolution of the fatigue state was
generally slower than that of psychological disorder. Dur-
ing extended follow-up, women with a combination of
fatigue and psychological disorder ran a more persistent
course than either those with psychological disorder alone
or those with fatigue alone. Emergence of new cases of
fatigue, either alone (15/116) or in combination with psy-
chological disorder (7/116), was relatively rare. This find-
ing argues that the genesis of both aspects of the illness
complex was at the time of cancer treatment, rather than
being attributable to subsequent events.
These data suggest that CRF may be reasonably separated
into two temporally-defined groups. Firstly, a treatment-
associated fatigue state with at least one clear etiologic fac-
tor – anemia [51]. The data for the negative influence of
anemia on treatment-associated quality of life in general,
and fatigue in particular, and improvement in these
parameters following treatment with erythropoetin is well
documented [51]. Secondly, cancer-related fatigue
encompasses a group who has ongoing fatigue post-treat-
ment – termed here PCF. In this latter group several stud-
ies have suggested that that anemia is unlikely to account
for a significant proportion of cases of PCF [35,52]. Anal-
ysis of laboratory data from a subset of 47 subjects in the
present report, revealed no association between lowered
hemoglobin and the development of PCF (data not
shown). Studies reported by Broeckel et al [29] and Bower
et al [23] indicated that fatigue was more severe among
patients with menopausal symptoms. Again, the data pre-
sented here showed no association between the fatigue
state and induction of menopause. Similar findings indi-
cating that fatigue states and menopausal symptoms are
independent have recently been reported [53]. The rela-
tionship to the intensity of the original treatment is
unclear, with some studies suggesting chemotherapy
[23,30] and combination therapy [31], are more likely to
be associated with protracted fatigue, and others finding
no such association [32]. Taken overall it would appear
that anemia and menopause do not provide a sufficient
explanation for PCF.
These findings suggest that alternative hypotheses of the
genesis of PCF will need to be explored. For instance,
excessive production of pro-inflammatory cytokines that
are known to be associated with induction of fatigue in
the context of acute infection or immunotherapy, has
been proposed [54]. Greenberg [9] correlated elevations
in IL-1 levels with increasing fatigue scores in patients
treated for prostate cancer with radiotherapy. Similarly, a
cross-sectional study comparing 40 women with PCF five
years post therapy for early stage breast cancer with a
matched control group showed distinctive changes in
cytokine profiles and T cell subsets [55]. An alternative
endocrine hypothesis has been derived from recent data
examining changes in the cortisol response to stressors in
women with PCF suggesting that changes in the hypotha-
lamic-pituitary-adrenal (HPA) axis may be relevant [56].
Such disturbances have also been implicated in relation to
chronic fatigue syndrome [57].
Conclusion
These preliminary findings emphasize the need for pro-
spective data to document changes in relevant clinical and
psychological parameters as well as putative biomarkers,
in a longitudinal fashion to better understand the cause-
and-effect relationships with illness outcomes in cancer
survivors.
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